Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

We just covered 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026 and Myriad Genetics, Inc. (NASDAQ:MYGN) ranks 8th on this list.

Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenview Capital since the third quarter of 2019. Back then, this position comprised 3.6 million shares. Since then, the fund has trimmed or increased this holding on a periodic basis. At one point in 2023, this position comprised close to 5.3 million shares. Filings for the fourth quarter of 2025 show that the fund owned almost 4.6 million shares in the firm, the same as in the previous quarter. Myriad is a molecular diagnostics and precision medicine company that develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.

Piper Sandler Maintains Overweight Rating on Blue Owl Capital (OWL)

Myriad Genetics, Inc. (NASDAQ:MYGN) has been unable to sway Wall Street despite years of restructuring. In Q1 2026, the firm reported a GAAP net loss of $34.1 million. Critics argue that if the company couldn’t find a path to profit during the height of the genetic testing boom, it is unlikely to do so now as competition intensifies. The bears also argue that the firm is losing share of wallet in the broader molecular diagnostics space. 12-month revenue growth of 5.7% significantly trails the US market average of 11.3%. Analysts at TD Cowen and Wells Fargo recently lowered their price targets on the stock following the Q1 miss.

While we acknowledge the risk and potential of MYGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MYGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.